In the News | Citizen Health Press Highlights

HIPAA. State laws. AI. Trust. Privacy leaders Deven McGraw, Tina Grande (Healthcare Trust Institute), Lucia Savage (Omada Health), and Robin Strongin (HealthDame) break down what protecting your health data looks like—and how AI is redefining patient control and consent.

Healthcare interoperability is moving quickly with major updates from CMS, ONC, and new rules shaping how payers and providers share data. In this episode of InteropChat, we bring together top experts to unpack what these changes mean for health systems, policy leaders, and technology innovators.

From Endpoints News Health Tech newsletter: Now, Citizen is building an AI advocate that can summarize personal health data, ideally making it easier to use those data in future doctor’s appointments. As a standalone company, Vij said, it can move faster than it might have inside a larger company, especially as AI speeds up what teams are able to do.

At its core, Citizen Health is building a beautiful consumer platform that brings together every piece of a patient’s health journey—clinical data, genetic information, imaging, patient-reported outcomes, and claims.

Citizen Health, a patient-powered platform transforming rare disease care, announced today it has raised $30 million in Series A funding. The round was led by 8VC, with participation from Transformation Capital and Headline, bringing the company's total funding to $44 million since its December 2023 launch.

Why it matters: Citizen aims to equip people with rare diseases, who often face medical dead ends, with an AI-powered advocate to navigate care and interpret records.

“We have our own proprietary database that we have built from scratch over many years to pull together every single e-fax number, every single email for every health information management department or medical records department,” for every single provider or hospital institution in the U.S., Citizen CEO Farid Vij told ...

There was little hope only a few years ago of treatments for kids with ultrarare SLC13A5 or FOXG1 syndromes. Drug companies were loathe to take on the cost of discovering and developing therapies, much less expensive and risky clinical trials, for genetic conditions with only a couple hundred patients.

"We orchestrate Gemini 2.5 Flash and Gemini 2.5 Pro models within a LangGraph‑powered multi‑agent framework, ensuring the most relevant evidence reaches patients and caretakers without hallucinations." - Daniel Wang, CTO, Citizen Health

Healthcare data sharing is evolving rapidly across CMS, ONC, and the entire industry. In this first episode of InteropChat, we brought together four top experts to break down what's happening and what's next.

"It has been several years since I last wrote a blog post about SCN8A. A wide range of clinical presentations have been described since, and significant progress has been made towards understanding the disease mechanism. However, SCN8A-related disorders have not become less puzzling."

Together, the organizations will establish a partnership focused on neuromuscular disorders, including limb-girdle muscular dystrophies (LGMDs), Charcot-Marie-Tooth (CMT) disease, nemaline myopathy (NM), myotonic dystrophies, and related conditions.